Subject Index to Volume 73

A

Acetylcholine
in cochlea, 328–335
biochemical evidence for, 328
chemical neuroanatomy support for efferent neurotransmitter role, 329–330
lateral efferent innervation, 329–330
medial efferent innervation, 329
functional implications of cholinergic olivocochlear neurotransmission, 333–334
lateral efferents, 334
medial efferents, 333–334
modulation of pacemaker currents, 215–217
Acetylcholine receptors, in cochlea, 330–333
muscarinic receptors coupled to inositol phosphate cascade, 330–331
nicotinic receptors, 331–333
in isolated outer hair cells, 332–333
in organ of Corti, 331–332
other cholinergic receptor types, 333
Acetylcholinesterase, tachykinin degradation, 244
Acids, gastric, gastroduodenal mucosal protection. *See* Gastroduodenal mucosal protection
Adenine nucleotide(s), binding affininty of cholecystokinin receptors and, 705–706
Adenosine
modulation of pacemaker currents, 217
neuroactive effects in cochlea, 342–343
Adenosine 3′,5′-cyclic monophosphate
calcium regulation in blood cells and, 562
in cardiovascular aging, 433–435
intracellular messenger for cholecystokinin receptors, 713
Adenosine 5′-triphosphate, modulation of pacemaker currents, 217–218
neuroactive effects in cochlea, 343–344
Adenylate cyclase
in cardiovascular aging, 433
cholecystokinin receptor signal transduction and, 710
Adrenal gland, tachykinin functions in, 264
Adrenal medulla, intracerebral grafting of adrenal medulla tissue, 606
in Parkinson's disease, 607
β-Adrenergic agonists
effect on calcium currents in sinoatrial node, 214–215
effect on delayed rectifier potassium current and hyperpolarization-activated current, 215
β-Adrenergic receptor system
in cardiovascular aging
β-adrenergic receptor response in chronic heart failure vs. that in healthy aging heart, 436
β-adrenergic receptors and aging, 432–433
cardiovascular target organ response to β-adrenergic stimulation in, 430–431
modulation of cardiac volumes and heart rate during exercise, 429
vascular responses and aging, 431–432
desensitization with age, 435–436
α_1-Adrenoceptors, in myocardium, functional aspects and transmembrane signaling mechanisms, 469–481. *See also* Myocardium, α_1-adrenoceptors in
Aerobic capacity, aging and, 436–438
effect of chronic physical conditioning on aerobic capacity in older humans, 438–440
Age/aging
aerobic capacity and, 436–438
assessment of aging
in humans, 725–726
value of animal models, 726–727
blood pressure and, 746–748
cardiovascular regulatory mechanisms and, 413–453. *See also* Cardiovascular aging
cellular and molecular mechanisms, 149–157
causes of cellular aging, 152–157
error theories, 152–154
program theories, 154–157
cellular senescence. *See* Senescence in vitro
error theories of cellular aging, 152–154
altered protein degradation, 154
cross-linking, 153
error catastrophe, 153–154
free radicals, 153
rate of living, 152–153
somatic mutations, 153
waste product accumulation, 153
life-prolonging effects of caloric restriction, 150
long-lived mutants, 150
program theories of cellular aging, 154–157
codon restriction, 155
inactivation of multicopy DNA sequences, 155
shortening of telomeres, 155
terminal differentiation, 155–157
evolution of aging, 149
in intracerebral grafting
donor age, 584
host age, 584–585
replicative senescence of human fibroblast-like cells in culture, 617–632. *See also* Senescence in vitro
Allergy, tachykinins in, 268–269
Alzheimer's disease, tachykinins in, 268
Amino acids
blood-brain barrier transport, vasopressin and, 508–509
excitatory
cochlear pathology and, 347–348
in efferent cochlear neurotransmission, 342
in inner hair cell neurotransmission. *See* Glutamate
γ-Aminobutyric acid, in cochlea, 335–337
functional implications, 336–337
as neurotransmitter in both olivocochlear innervations, 335–336
Aminoglycoside antibiotics, ototoxicity, cholinergic medial efferent innervation in, 348–350
α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid, neurotoxicity, 325
α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors, in cochlea, 322–324
Amygdala, tachykinin functions in, 250
Analgesics, sensitivity of event-related brain potentials to, 655–659
Angiogenesis, tumors, proteinases in, 184–185

Angiotensin
blood-brain barrier receptors, binding characteristics and signaling pathways, 503
blood-brain barrier transport and, 508
Anions, organic
choroid plexus transport, 778
hepatic transport mechanisms, 775–776
renal secretion. *See* Kidney, organic anion transport
transport in other tissues, 776–777
Anterior segment of eye, tachykinin functions in, 255
Antibody(ies), to tachykinins, 241
Arachidonic acid
calcium regulation in blood cells and, 562
metabolites, active lymph propulsion and, 43
Artery(ies)
impedance, changes with aging, 420
stiffness and pressure, changes with aging, 417–420
structure and mechanical properties, changes with aging, 417–421
ventricular vascular interactions, changes with aging, 420–421
Arthritis, tachykinins in, 269
Ascending reticular system, tachykinin functions in, 253
Aspartate, in inner hair cell neurotransmission, 316–326
electrophysiological effects in cochlea, 320–321
endogenous aspartate release, 319–320
inactivation and replenishment of hair cell pool
aspartate aminotransferase and, 318
efferent uptake and inactivation, 318
localization in inner hair cells, 316–317
Atrial natriuretic peptide, secretion, endothelin and, 395
Atriopeptin
blood-brain barrier receptors, binding characteristics and signaling pathways, 504–505
blood-brain barrier transport and, 511–512
brain hemodynamics and, 512
tight junction permeability and, 512
water and ion fluxes and, 511–512
Auditory nerve-activating substance, neuroactive effects in cochlea, 344–345
Autonomic preganglionic nuclei, tachykinin functions in, 253–254
sacral parasympathetic nucleus, 254
sympathetic preganglionic cell coulmn, 253–254
Autoradiography, mapping endothelin receptors in kidney, 388
Axon(s)
differential blocking, in psychophysiological pain studies, 642–643
elongation and guidance in CNS, 590
X and Y retinogeniculate axon development. *See also* Retinogeniculate system
competition and (cat), 529–542

B

Bicarbonate
gastroduodenal secretion
duodenal mucosal secretion, 828–829
effect of luminal acid, 829–831
gastric secretion, 827–828
neural control of, 831–833
interstitial, protective role in stomach and duodenum, 840–841
Bile acids, in organic anion transport in liver, 776
Bile pigments, in organic anion transport in liver, 776
Blister technique, interstitial protein concentration, 17
Blood-brain barrier, 489–490
angiotensin-induced transport alterations, 508
angiotensin receptors, binding characteristics and signaling pathways, 503
atriopeptin-induced transport alterations, 511–512
brain hemodynamics and, 512
tight junction permeability and, 512
water and ion fluxes, 511–512
atriopeptin receptors, binding characteristics and signaling pathways, 504–505
bradykinin-induced transport alterations, 510
brain hemodynamics and, 510
tight junction permeability and, 510
bradykinin receptors, binding characteristics and signaling pathways, 504
capillary-peptide interactions, 490–502
methodological considerations, 490–492
peptide accumulation by blood-brain barrier-protected regions, 496–502
peptide accumulation by circumventricular organs, 492–496
uptake of blood-borne peptides by brain, 492
endothelial cells of microvasculature and peptides. *See* Blood-brain barrier, capillary-peptide interactions
endothelin-induced transport alterations, 510–511
endothelin receptors, binding characteristics and signaling pathways, 504
insulin-induced transport alterations, 512
insulin receptors, binding characteristics and signaling pathways, 505
peptide accumulation by blood-brain barrier-protected regions, 496–502
general aspects, 496–497
peptide molecules in transfer or after transfer through the tight endothelium, 497–498
peptide molecules nonspecifically retained by endothelial cells, 498
peptide molecules specifically bound to endothelial cells, 498–502
peptide receptors at, 502–507
binding characteristics and signaling pathways, 502–505
receptor distribution, 506
receptor localization, 505–506
receptor regulation, 506–507
transport
angiotensin-induced alterations, 508
bradykinin-induced alterations, 510
endothelin-induced alterations, 510–511
insulin-induced alterations, 512
peptide-induced alterations, 507–513
peptides and, 490–514
substance P and, 513
vasoactive intestinal peptide and, 513
vasopressin-induced alterations, 508–510
vasopressin-induced transport alterations, 508–510
amino aciad transport, 508–509
hemodynamic effects, 509–510
tight junction permeability and, 509
water and ion transport, 509
vasopressin receptors, binding characteristics and signaling pathways, 503–504
Blood cells
calcium channels in, 549–553
calcium entry through plasma membranes, 550–553
calcium release from internal stores, 549–550
calcium pumps
of intracellular membranes, 554–556
of plasma membranes, 553–554
calcium regulation in, 547–570. *See also* Calcium, in blood cells
calcium buffers, stores, and transporters, 556–559
calcium-transporting systems, 549–556
experimental approaches, 548–549

models of calcium spiking, 566–567
alternative models, 567
analog-to-digital conversion of signals, 567
calcium-induced calcium release model, 566–567
inositol 1,4,5-trisphosphate-calcium cross-coupling model, 566
physiological significance of cytosolic calcium signaling, 567–570
cell proliferation and differentiation, 569
cell secretion and phagocytosis, 568–569
cell shape, movements, and adherence, 567–568
pathological conditions, 569–570
potassium channels in, 557
repeated calcium spikes (oscillations), 565–566
sodium-calcium exchange and, 556
sodium-potassium pump in, 557
solitary calcium spikes, 564
time-dependent changes of cytosolic calcium, 560–567
transmembrane signaling, 560–564
arachidonic acid and phospholipase A_2 in, 562
1,2-diacylglycerol and protein kinase C in, 561–562
inositol 1,4,5-trisphosphate and phospholipase C in, 560–561
other intracellular messengers and related enzymes in, 562–563
types, 547–548
zinc in, 103

Blood pressure
age-related changes, 746–748
dynamic exercise and, changes with aging, 428
orthostatic stress and, changes with aging, 425

Blood vessels
age-related changes. *See* Cardiovascular aging, vascular system
pulsation, lymph propulsion in collecting ducts and, 39–40
tachykinin function in, 262

Body fluids, extracellular fluid volume. *See* Extracellular fluid volume

Bone, tachykinin functions in, 264–265

Bradykinin
active lymph propulsion and, 43
blood-brain barrier receptors, binding characteristics and signaling pathways, 504
blood-brain barrier transport and, 510
brain hemodynamics and, 510
tight junction permeability and, 510

Brain
capillary-peptide interactions, 490–502. *See also* Blood-brain barrier
methodological considerations, 490–492
peptide accumulation by blood-brain barrier-protected regions, 496–502
peptide accumulation by circumventricular organs, 492–496
uptake of blood-borne peptides by brain, 492
developing, taurine in, 126–131

Buffering
hydrostatic, in edema prevention, 26
interstitial buffering mechanisms in control of interstitial fluid volume, 28
lymphatic buffering of interstitial fluid volume, 57–60
oncotic, in edema prevention, 26–28

Burn injury, edema in, 29

C

C-afferent neurons, tachykinins and. *See* Tachykinins

Calcineurin. *See also* Protein serine/threonine phosphatases, protein phosphatase 2B
calcium regulation in blood cells and, 563

Calciosomes, calcium regulation in blood cells and, 559

Calcitonin gene-related peptide, in cochlea, 341–342
functional data, 341–342
neuroanatomical data, 341

Calcium
in blood cells, 547–570. *See also* Blood cells, calcium regulation in
calcium buffers, stores, and transporters, 557–560
buffering by plasma membrane and cytosol, 557–558
endoplasmic reticulum and calciosomes, 558–559
granules and vesicles, 559–560
mitochondria and nucleus, 559
physiological significance of cytosolic calcium signals, 567–570
time-dependent changes of cytosolic calcium, 560–567
models of calcium spiking, 566–567
repeated calcium spikes (oscillations), 565–566
solitary calcium spikes, 564
transmembrane signaling, 560–564
transporting systems, 549–557
calcium channels, 549–553
calcium pumps, 553–556
interacting transporters, 556–557
sodium-calcium exchange, 556
cytosolic free calcium, in neutrophil signal transduction, 799
intracellular
changes in cardiac muscle, 442–443
modulation of pacemaker currents, 218
myocardial α_1-adrenergic stimulation and, 481
pacemaker oscillations triggered by, 213–214
tachykinin-induced elevation, 243
intracellular messenger for cholecystokinin receptors, 711–712

Calcium channels, in blood cells, 549–553
calcium entry through plasma membranes, 550–553
calcium release from internal stores, 549–550

Calcium currents
acetylcholine-induced reduction of, 216
effects of β-adrenergic agonists, 214–215
myocardial, effect of α_1-adrenoceptor agonists, 474–475
in pacemaker depolarization, 211–121
in sinoatrial node, 204–205

Caloric restriction, life-prolonging effects, 150

Calpain, calcium regulation in blood cells and, 563

Capsaicin, 241–242
effects on C-afferent neurons, 242
mechanisms of action, 242

Capsule techniques, interstitial fluid hydrostatic pressure measurement, 18–19

Carcinoid syndrome, tachykinins in, 269

Cardiac output
dynamic exercise and, changes with aging, 427
resting, changes with aging, 424–425, 737

Cardiac pacemaking
mechanisms, 210–214
oscillations of membrane potential in absence of delayed rectifier potassium current, 213
pacemaker depolarization. *See* Cardiac pacemaking, pacemaker depolarization
pacemaker oscillations triggered by intracellular calcium, 213–214
summary, 214
modulation of pacemaker currents, 214–218
acetylcholine, 215–217
adenosine and adenosine triphosphate, 217–218
intracellular calcium, 218
intracellular protons, 218
norepinephrine, 214–215
pacemaker depolarization
background current in, 211
calcium currents in, 211–212

delayed rectifier potassium current, 211
hyperpolarization-activated current in, 212–213
in sinoatrial node, 197–219. *See also* Sinoatrial node
isolated pacemaker cells, 198–201
mechanism of, 210–214
membrane currents of sinoatrial node cells, 201–210
regulation of pacemaker currents, 214–218
single sinoatrial node cells vs. multicellular preparations, 200–201
accumulation and depletion of ions, 201
diffusion of intrapipette substances into the cell, 201
voltage-clamp conditions, 200–201
washing out phenomena, 201

Cardiovascular aging
aerobic capacity and aging, 436–438
effect of chronic physical conditioning on aerobic capacity in older humans, 438–440
arterial structure and mechanical properties at rest in younger and older humans, 417–421
arterial impedance, 420
arterial stiffness and pressure, 417–420
ventricular vascular interactions, 420–421
blood pressure and, 746–748
cardiac filling (diastolic) properties at rest in younger and older humans, 421–423
cardiac structure and compliance and, 729–733
animal studies, 729–731
in human subjects, 731–733
cardiac dimensions, 731–732
chemical and ultrastructural changes, 733
diastolic compliance, 732–733
cardiac structure at rest in younger and older humans, 416–417
cardiovascular response to acute stress, 425–429
dynamic exercise, 427–429
arterial pressure, vascular resistance, and impedance, 428–429
end-diastolic and end-systolic volumes, 427–428
heart rate, stroke volume, and cardiac output, 427
orthostatic stress, 425–426
heart rate and cardiac volume, 425–426
peripheral vascular resistance and arterial pressure, 425
pressor stress, 426–427
cardiovascular response to exercise and training, 754–755. *See also* Aerobic capacity
final considerations, 755–756
longitudinal axis of cardiovascular function, 727–728
myocardial function and, 733–737
levels of cardiac output during rest and light activity, 737
membrane and excitation-contraction events, 733–736
findings in animals, 733–734
findings in humans, 734–736
pacemaker activity and heart rate, 736–737
neurohormonal control mechanisms, 748–754
adrenergic and cholinergic receptors, 749–750
cardiovascular reflex control, 751–752
cardiovascular response to psychosocial stimuli, 752–754
efferent sympathohormonal and parasympathetic control, 750–751
general aspects, 748–749
physiology, 725–756
principles of structural geometry of heart and vessels, 728–729
regulatory mechanisms in, 413–453
aerobic capacity and aging, 436–438
cardiovascular response to acute stress, 425–429
cardiovascular structure and function at rest in younger and older humans, 416–425
effect of chronic physical conditioning on aerobic capacity in older humans, 438–440
structural and functional changes with aging in animals, 440–453
sympathetic modulation of function, 429–436
structural and functional changes in animals, 440–453
cardiac muscle and myocyte changes, 442–447
action potential and membrane currents, 442
cytosolic calcium concentrations, contraction, and relaxation, 442–444
myocardial stiffness, 446–447
myofilament proteins, 446
sarcoplasmic reticulum function, 444–445
sodium regulation, 445
spontaneous sarcoplasmic reticulum calcium oscillations and their functional sequelae, 445–446
cardiac structure, 440–441
cardiac structure and compliance, 729–731
coronary flow, oxygen consumption, and oxidative metabolism, 447–448
myocardial function, membrane and excitation-contraction events, 733–734
physical conditioning effects on cardiac muscle of senescent rats, 452–453
regulation of cardiac contraction, 441–453
excitation-contraction coupling mechanisms, 441–442
similar effects of aging and experimental pressure overload, 448–452
excitation-contraction mechanisms, 448–450
response of older rat heart to chronic hemodynamic overload, 451–452
transduction mechanisms of pressure loading and aging, 450–451
structural and functional changes in humans
cardiac dimensions, 731–732
cardiac structure and compliance, 731–733
chemical and ultrastructural changes in myocardium, 733
diastolic compliance, 732–733
myocardial function
levels of cardiac output during rest and light activity, 737
membrane and excitation-contraction events, 734–736
pacemaker activity and heart rate, 736–737
sympathetic modulation of cardiovascular function, 429–436
β-adrenergic receptor response in chronic heart failure vs. that in healthy aging heart, 436
efferent sympathohormonal and parasympathetic control, 750–751
in intact organisms, 429–431
β-adrenergic modulation of cardiac volumes and heart rate during exercise, 429
cardiovascular target organ response to β-adrenergic stimulation with aging, 430–431
neurotransmitter elaboration during stress, 429–430
isolated tissues or cells, 431–436
β-adrenergic receptors and aging, 432–433
cAMP, protein kinase activation, intracellular phosphorylation, and aging, 433–435
cardiac responses and aging, 432
desensitization of β-adrenoceptor system with age, 435–436
guanine nucleotide-binding protein, adenylate cyclase activity, and aging, 433
vascular responses and aging, 431–432
systolic myocardial and cardiac pump function at rest in younger and older humans, 423–425
cardiac output, 424–425
cardiac volumes and ejection fraction, 423
heart rate and rhythm, 423–424
myocardial contractile properties, 423

vascular system, 737–746
capillaries, 741
cerebral vascular bed, 745–746
coronary vascular bed, 744
endothelial cells, 738
important systemic circuits, 744–746
pulmonary vascular bed, 742–744
renal vascular bed, 744–745
resistance vessels, 741
systemic veins and blood volume, 742
vascular smooth muscle, 737–738
windkessel vessels, 738–741
Cardiovascular system
longitudinal axis of cardiovascular function, 727–728
neurohormonal control mechanisms, aging and, 748–754
principles of structural geometry of heart and vessels, 728–729
regulation of function, 414–416
in aging. *See* Cardiovascular aging
response to intracerebroventricular tachykinins, 251
tachykinin function in, 262–263
Carotid body, tachykinin function in, 262–263
Cations, organic
choroid plexus transport, 785–786
hepatic transport, 786–787
renal secretion. *See* Kidney, organic cation transport
Cell culture, replicative senescence of human fibroblast-like cells in culture, 617–632. *See also* Senescence in vitro
Cell cycle
control of, protein serine/threonine phosphatases in, 684–690
position of arrested (senescent) cells in vitro, 622–623
Cellular aging. *See* Age/aging, cellular and molecular mechanisms; Senescence in vitro
Cerebellum, intracerebral grafting in, 595–596
Cerebrospinal fluid, tachykinins in, 269
Chemical stimulation
pain induced by, 649
in psychophysiological pain studies, 641–642
Cholecystokinin
actions on pancreatic acini, 701–702
binding to pancreatic acini. *See* Cholecystokinin receptors
physiology, 701
Cholecystokinin receptors, pancreatic, 702
adenylate cyclase and, 710
age-related expression of, 709
binding characteristics, 703–708
affinity states, 703–706
regulation by guanine and adenine nucleotides, 705–706
studies with isolated membranes, 704–705
studies with isolated pancreatic acini, 703–704
agonist binding specificity, 706–707
antagonist binding and specificity, 707–708
characterization, 702–709
desensitization, 708–709
guanine nucleotide-binding protein interaction, 709
intracellular messengers of, 710–713
calcium ion, 711–712
cyclic nucleotides, 713
diacylglycerol, 712–713
inositol trisphosphate, 710–711
localization and internalization of, 708
molecular structure, 702–703
phospholipase C activation, 709–710
regulation of physiological processes induced by, 713–716
relation of physiological responses to occupancy of receptor, 713–714
use of partial agonist JMV-180 to relate receptor affinity states to distinct actions, 714–716
signal transduction mechanisms, 709–710
Choroid plexus
organic anion transport, 778
organic cation transport, 785–786
Chromatin, zinc deficiency and, 93
Cochlea
adenosine in, 342–343
adenosine 5′-triphosphate in, 343–344
afferent innervations, 310–313
inner hair cell afferent innervations, 310–313
outer hair cell afferent innervation, 313
auditory nerve-stimulating substance in, 344–345
base vs. apex neurochemical and functional distinctions in cochlea, 353–354
efferent neurotransmitters and neuromodulators, 328–342. *See also specific agents*
acetylcholine, 328–335. *See also* Acetylcholine
γ-aminobutyric acid, 335–337
calcitonin gene-related peptide, 341–342
coexistence of efferent neurotransmitters/neuromodulators and their possible functional consequences, 350–352
dopamine, 337–338
dynorphins, 340–341
enkephalins, 338–340
excitatory amino acids, 342
efferent olivocochlear innervations, 313–315
lateral efferent innervations, 313–314
origin, 313–314
projections, 314
medial efferent innervation, 314–315
aminoglycoside antibiotic ototoxicity and, 348–350
origin, 314
projections, 314–315
excitatory amino acid receptors in
α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid and/or kainate receptors, 322–324
agonist data, 322–323
antagonist data, 323–324
N-methyl-D-aspartate receptors, 322
other receptors, 324
glutamatergic hypothesis of inner hair cell neurotransmission, 316–326
electrophysiological effects of glutamate and aspartate in cochlea, 320–321
inactivation and replenishment of hair cell pool of glutamate, 317–319
aspartate aminotransferase in glutamate and aspartate synthesis, 318
efferent uptake and glutamate and aspartate inactivation, 318
glutamate-glutamine cycle, 317–318
other mechanisms of glutamate or aspartate inactivation in cochlea, 318–319
localization of glutamate and aspartate in inner hair cells, 316–317
monitoring of endogenous glutamate and aspartate release, 319–320
nature of excitatory amino acid receptors in organ of Corti, 321–324
α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid and/or kainate receptors in cochlea, 322–324
N-methyl-D-aspartate receptors in cochlea, 322
neurotoxicity of glutamate analogues, 324–326
α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid, 325
glutamate, 326

kainate, 324–325
N-methyl-D-aspartate, 325–326
quisqualate, 325
hair cell neurotransmitters, 316–328
glutamatergic hypothesis of inner hair cell neurotransmission, 316–326. *See also* Cochlea, glutamatergic hypothesis of inner hair cell neurotransmission
outer hair cell neurotransmitter(s), 326–328
an excitatory amino acid as a putative outer hair cell neurotransmitter, 327
miscellaneous candidates, 327–328
histamine in, 345
neuroactive substances, 342–345
adenosine, 342–343
adenosine 5′-triphosphate, 343–344
auditory nerve-stimulating substance, 344–345
histamine, 345
neurotransmitters and neuromodulators in, 309–354
efferent neurotransmitters and neuromodulators, 328–342
hair cell neurotransmitters, 316–328
neuronal circuitry of organ of Corti, 310–316
other neuroactive substances, 342–345
neuroactive substances, taurine, 344
paracrine neuromodulation, 352–353
pathology
cholinergic medial efferent innervation in ototoxicity of aminoglycoside antibiotics, 348–350
excitatory amino acid-related, 347–348
sympathetic innervation(s), 315–316
taurine in, 344
Cold pressure test, in psychophysiological pain studies, 641
Cold stimulation, in psychophysiological pain studies, 641
Collagen, interstitium, 2–3
Colloid osmotic pressure
interstitium, 15–18
plasma, 22
Compression, external, lymph propulsion in collecting ducts and, 39
Constipation, chronic, tachykinins in, 269
Coronary flow, changes with aging, in animals, 447–448
Cranial motor nuclei, tachykinin functions in, 254

D

Dark rearing, effects on retinogeniculate axon development (cat), 540
Dental pulp
interstitial fluid hydrostatic pressure, micropuncture technique, 20
tachykinin functions in, 256
Deoxyribonucleic acid, synthesis
in aging cell cultures, 621–622
capacity of fibroblasts in culture, 627–629
inhibitors, in senescent cells, 624
Dermatologic disorders, zinc deficiency and, 101
Developmental biology, zinc biochemistry in, 93–95
Diabetes mellitus, experimental, tachykinins in, 244
Diacylglycerol, intracellular messenger for cholecystokinin receptors, 712–713
1,2-Diacylglycerol, calcium regulation in blood cells and, 561–562
Dopamine, in cochlea, 337–338
Dorsal vagus nucleus, tachykinin functions in, 253
***Drosophila* protein phosphatases,** 679
Duodenum
mucosal protection. *See* Gastroduodenal mucosal protection
mucosal secretion of bicarbonate, 828–829
Dynorphins, in cochlea, 340–341

E

Edema
in acute inflammation, 29–30
in burn injuries, 29
lymphedema, 28–29
myxedema, 29
preventive mechanisms, 26–28
hydrostatic buffering, 26
interaction between buffering mechanisms, 28
lymphatic buffering of interstitial fluid volume, 57–60
lymphatic safety factor, 28, 59–60
oncotic buffering, 26–28
Eicosanoids, active lymph propulsion and, 43–44
Elastin, interstitium, 5
Electrical stimulation, in psychophysiological pain studies, 639–640
Endocrine system
zinc deficiency and, 102
zinc in, 96–97
Endoplasmic reticulum, calcium regulation in blood cells and, 558–559
Endothelin
blood-brain barrier receptors, binding characteristics and signaling pathways, 504
blood-brain barrier transport and, 510–511
discovery, 376
genes, molecular biology, 380–382
mode of action, autocrine/paracrine peptide or circulating hormone, 379–380
pharmacological blockade of action, 387–388
renal actions, 390–398
glomerular filtration rate and, 392–393
mesangial cell biology and, 393
perspectives, 398
possible role in renal pathophysiology, 396–398
regulation of renal hemodynamics, 390–392
intrarenal infusions of endothelin to the kidney in situ and to isolated perfused kidney, 391–392
local control of renal hemodynamics, 392
systemic infusions of endothelin, 390–391
sodium excretion, 393–395
atrial natriuretic peptide secretion, 395
filtered load of sodium, 394
renin-angiotensin-aldosterone system, 394–395
sodium-potassium-adenosinetriphosphatase in collecting duct, 395
water reabsorption, 395–396
renal secretion, 389–390
signal transduction in nucleus, 387
structure, 376–377
synthesis and secretion, 378–379
transmembrane signaling, 382–387
Endothelin receptors, renal
molecular characterization of renal endothelin binding sites, 389
receptor autoradiography in situ, 388
Endotoxin, active lymph propulsion and, 44
Enkephalinase, tachykinin degradation, 243–244
Enkephalins, in cochlea, 338–340
in lateral efferent innervation, 338–339
neuroactive effects, 339–340
coupling of cochlear opioid receptors to an adenylate cyclase second messenger system, 339–340
neuroactive function of different proenkephalin-related peptides, 339
stereospecific opioid binding sites in cochlea, 339
release from cochlear tissues, 339

Enzyme(s)
substance P-degrading, 243-244
zinc, 82-86
Epidermal growth factor, in gastrointestinal epithelial proliferation and restitution, 843
Error catastrophe theory, 153, 627
Event-related potentials (ERPs)
early near-field ERPs, 652-653
effects of analgesics on ERPs and pain ratings, 656-659
monitoring of anesthesia and analgesia, 658-659
nonopioid analgesics, 656-657
opioid analgesics and other centrally acting drugs, 657-658
endogenous, 655
intermediate and late near-field ERPs, 653-655
changes in ERPs due to repeated stimulation, 655
cortical generators, 653
endogenous components of pain-related potentials, 655
event-related magnetic fields, 653-654
relation of ERPs to stimulus intensity and pain reports, 654-655
pain-related, 652-659
clinical applications in neurology and related fields, 659
early near-field ERPs, 652-653
effects of analgesics, 656-658
intermediate and late near-field ERPs, 653-655
monitoring of anesthesia and analgesia, 658-659
ultralate ERPs, 655-656
pain sensation and, 652-659
ultralate ERPs, 655-656
Exercise
cardiovascular response in elderly subjects, 754-755
dynamic, cardiovascular response to, changes with aging, 427-429
endurance training
cardiovascular response in elderly subjects, 754-755
effect on aerobic capacity in older humans, 438-440
effects on cardiac muscle of senescent rats, 452-453
Extracellular fluid volume, interstitial-lymphatic control, 1-61
composition and properties of interstitium, 1-21. *See also* Interstitium
edema and, 28-30
in acute inflammation, 29-30
in burn injuries, 29
lymphedema, 28-29
myxedema, 29
edema-preventing mechanisms, 26-28
hydrostatic buffering, 26
interaction between buffering mechanisms, 28
lymphatic safety factor, 28
oncotic buffering, 26-28
interstitial buffering mechanisms in, 28
lymph flow in hyperfiltration states, 53-60
lymph formation and transport, 30-53. *See also* Lymph; Lymphatic system
transcapillary exchange of fluid and proteins, 21-30
interstitial edema-preventing mechanisms, 26-28
transcapillary protein transport, 23-26
transcapillary water transport, 21-23
transcapillary protein transport, 23-26
capillary filtration coefficient and, 24
capillary reflection coefficient for proteins and, 24
determinants of, 24-25
increased capillary filtration and, 25-26
permeability-surface area product and, 24-25
regulation of capillary permeability, 25-26
transcapillary water transport, 21-23
capillary filtration coefficient and, 23
capillary hydrostatic pressure and, 22-23
capillary reflection coefficient for proteins and, 22
determinants of, 21-23
interstitial pressures and, 23
plasma colloid osmotic pressure and, 22
Extracellular matrix
alterations during tumor invasion, 164-165
composition and structure, 161-164
degradation, proteinases in, 165-170
Extremities, movements, lymph propulsion in collecting ducts and, 38-39
Eye
tachykinin functions in, 255-256
zinc in, 97-98

F

Familial dysautonomia, tachykinins in, 268
Fatigue, nociceptor, pain and, 651
Fibroblasts, replicative senescence of human fibroblast-like cells in culture, 617-632. *See also* Senescence in vitro
Filtration coefficient, capillary, 23
transcapillary protein transport and, 24
Free radical damage theory, 153, 627

G

Ganglion cell, retinal
axonal arbors in lateral geniculate nucleus. *See* Retinogeniculate system
death of, 535-536
development, 531
morphology, 530
Gastroduodenal mucosal protection, 823-847
epithelial proliferation and restitution, 842-847
epidermal growth factor in, 843
epithelial restitution, 843-845
mucosal cell proliferation and turnover, 842-843
recovery from acute and chronic damage, 845-847
gastroduodenal mucus gel, 824-827
adherent mucus gel secretion, 824-825
adherent mucus gel structure, 825-827
mechanisms of acid disposal in stomach, 836-841. *See also* Stomach, acid disposal
mucosal bicarbonate secretion, 827-834
drug and hormone effects, 833-834
duodenal mucosal bicarbonate secretion, 828-829
effect of luminal acid on, 829-831
gastric bicarbonate secretion, 827-828
neural control of, 831-833
mucus-bicarbonate barrier protection against acid and pepsin, 834-836
protection against pepsin, 835-836
surface neutralization and unstirred layer, 834
surface pH gradients, 834-835
Gastrointestinal tract
epithelial proliferation and restitution, 842-847
epidermal growth factor in, 843
epithelial restitution, 843-845
mucosal cell proliferation and turnover, 842-843
recovery from acute and chronic damage, 845-847
mucosal protection. *See* Gastroduodenal mucosal protection
tachykinin functions in, 257-260
actions on enteric neurons and their role as neurotransmitters, 258

gastrointestinal motility and, 258–259
presence of tachykinins and their receptors, 257
release of tachykinins, 257
secretion, 259
vascular responses and mucosal protection, 259–260
zinc deficiency and, 101–102
zinc physiology, 91–92
Gene(s)
codon restriction, cellular aging and, 155
endothelin, molecular biology, 380–382
inactivation of multicopy DNA sequences, cellular aging and, 155
preproendothelin gene expression, 389
senescence-specific, 155–157, 626
in senescent fibroblasts in culture, 629–631
tachykinins, 237
Gene regulatory proteins, zinc in, 87–90, 94–95
Geniculate nucleus, lateral, development of retinal ganglion cell projections to. *See* Retinogeniculate system
Genital tract
female, tachykinin functions in, 264
male, tachykinin functions in, 264
Glia, tachykinin functions in, 254
Globus pallidus, tachykinin functions in, 248
Glomerular filtration rate, endothelin and, 392–393
Glossopharyngeal ganglia, tachykinin functions in, 253
Glutamate
in inner hair cell neurotransmission, 316–326
electrophysiological effects in cochlea, 320–321
endogenous aspartate release, 319–320
inactivation and replenishment of hair cell pool, 317–319
aspartate aminotransferase in, 318
efferent uptake and inactivation, 318
glutamate-glutamine cycle, 317–318
localization in inner hair cells, 316–317
neurotoxicity, 326
Glycosaminoglycans, interstitium, 3–5
Grafting, in central nervous system. *See* Intracerebral grafting
Granules, calcium regulation in blood cells and, 559–560
Growth and development
embryonic, zinc in, 92–93
postnatal, taurine and, 121–126
protein serine/threonine phosphatases in, 673–692. *See also* Protein serine/threonine phosphatases
taurine in, 119–136
Growth hormone, zinc and, 96
Guanine nucleotide(s)
binding affininty of cholecystokinin receptors and, 705–706
cyclic, intracellular messenger for cholecystokinin receptors, 713
Guanine nucleotide-binding protein
in cardiovascular aging, 433
coupling, myocardial α_1-adrenoceptors and, 479
interaction with cholecystokinin receptor, 709
Guanosine 5′-triphosphate-binding proteins
in neutrophil signal transduction, 798, 802–804
heterotrimeric GTP-binding proteins, 803–804
small GTP-binding proteins, 804
nicotinamide adenine dinucleotide phosphate (reduced) oxidase and, 809–810

H

Habenulo-interpeduncular system, tachykinin functions in, 250
Headache, tachykinins in, 269
Heart
age-related changes. *See* Cardiovascular aging
developing, taurine in, 134
tachykinin function in, 262
Heart failure, congestive, lymph flow response, 54–55
Heart rate
changes with aging, 736
dynamic exercise and
β-adrenergic modulation, 429
changes with aging, 427
orthostatic stress and, changes with aging, 425–426
resting, changes with aging, 423–424
Heat stimulation
pain induced by, 648–649
in psychophysiological pain studies, 641
Hematologic system. *See also* Blood cells
zinc deficiency and, 102–103
Hepatobiliary system, tachykinin function in, 260
Herpes zoster, tachykinins in, 269
Hippocampus
intracerebral grafting in, 596–598
aged animals, 598
aminergic and cholinergic tissue grafts, 596–597
hippocampal tissue grafts, 597
tachykinin functions in, 250
Hirschsprung's disease, tachykinins in, 268
Histamine
active lymph propulsion and, 43
neuroactive effects in cochlea, 345
Huntington's disease, tachykinins in, 268
Hyaluronan, interstitium, 3–5
net capillary filtrate and lymph flow as determinants of, 4–5
synthesis and extrusion, 3
turnover, 3–4
Hydrogen ion
gastric disposal of, mucosal blood flow in, 838–840
permeability of gastric epithelium to, 836–838
Hydrostatic pressure
capillary, 22–23
interstitial fluid, 10–13. *See also* Interstitium
Hyperalgesia
nociceptor sensitization and, 651–652
primary, 651–652
secondary, 652
Hyperpolarization-activated inward current
effects of β-adrenergic agonists, 215
in pacemaker depolarization, 212–213
in sinoatrial node, 207–209
Hypoproteinemia, lymph flow response, 56–57
Hypothalamus
intracerebral grafting in, 598–601
Brattleboro rat, 600–601
hypogonadal mouse, 598–600
tachykinin functions in, 250–251

I

Immune system
tachykinins in, 267
zinc and, 98–99
Immunology, intracerebral grafting, 585
Inflammation
acute, edema in, 29–30
involvement of capsaicin-sensitive fibers in, 265
tachykinins in, 265–267

flare and vasodilatation, 265–266
interactions with other mediators, 267
leukocyte activation, 266–267
wheal and plasma extravasation, 266
Inflammatory bowel disease, tachykinins in, 269
Inhibitory factors, regeneration in CNS and, 594–595
Inositol 1,4,5-trisphosphate
calcium regulation in blood cells and, 560–561
intracellular messenger for cholecystokinin receptors, 710–711
Insulin
blood-brain barrier receptors, binding characteristics and signaling pathways, 505
blood-brain barrier transport and, 512
Interocular competition, retinogeniculate axon arbor development and (cat), 532–537
competitive advantage (?) of Y axons in denervated laminae, 533–534
description of ocular segregation, 532
do Y axons sprout because they develop later, 534–535
can X axons sprout, 534–535
intracellular studies after monocular enucleation on embryonic day 44, 534
LGN development after prenatal monocular enucleation, 534
prenatal monocular enucleation, 534
elimination of ongoing binocular interactions postnatally, 532–533
capability of all retinal axons to sprout, 532–533
differential capacity of X and Y axons to sprout into denervated geniculate regions after monocular enucleation, 533
early studies, 532
intracellular studies of early postnatal monocular enucleation, 533
is height of X axons intrinsically determined, 536
other effects of early monocular enucleation, 535
role of interocular competition in eye-specific segregation, 535–536
cell death in the retina, 535–536
dynamics of eye-specific segregation, 536
elimination of mislocated side branches, 535
summary of interocular interactions, 536–537
Interstitium
compliance, 13–15
determinants of, 15
lung, 14–15
regulation of, 15
skeletal muscle and skin, 13–14
composition, 2–5
collagen, 2–3
elastin, 5
glycosaminoglycans, 3–5
plasma proteins, 5
electrical charge, 8
fluid volume, 15. *See also* Extracellular fluid volume
lymphatic buffering, 57–60
hydraulic conductivity, 8–9
inhomogeneity, 9–10
interaction between components, 5–7
collagen and glycosaminoglycans, 5
interstitial volume exclusion, 5–7
interstitial fluid hydrostatic pressure, 10–13
measurement, 18–21
capsule techniques, 18–19
direct comparison between techniques, 20–21
indirect estimates, 20
micropuncture technique, 20
tissue osmometry, 17–18, 20
wick techniques, 19–20
interstitial pressures, 10–13
imbibition pressure vs. interstitial fluid pressure, 12
solid tissue pressure, 12–13
total tissue pressure, 13
movement of molecules through, 9
physicochemical properties, 7–15
compliance, 13–15
electrical charge, 8
hydraulic conductivity, 8–9
inhomogeneity, 9–10
interstitial pressures, 10–13
mechanical properties of collagen fibers and skin, 7
movement of molecules through, 9
protein concentration and colloid osmotic pressure, 15–18
blister technique, 17
interstitial fluid sampled by cannulas/catheters, 18
lymph, 15–16
intestine, 16
lung, 16
skin and skeletal muscle, 15–16
tissue osmometry, 17–18
wick techniques, 16–17
volume exclusion, 5–7
excluding structure, 6–7
physiological importance, 7
Intestine(s)
interstitial edema-preventing mechanisms
hydrostatic buffering, 26
oncotic buffering, 27
interstitial fluid hydrostatic pressure
capsule technique, 19
wick technique, 20
lymph, protein concentration, 16
peristalsis, lymph propulsion in collecting ducts and, 38
Intracerebral grafting, 583–608
development in central nervous system, 586–592
afferent and efferent connectivity, 590–592
axon elongation and guidance, 590
histogenesis and differentiation, 586–587
migration and lamination, 587–588
neuronal maturation, 588–589
neurotransmitter phenotype, 589–590
methodological considerations, 584–586
donor age, 584
host age, 584–585
immunologic factors, 585
target access, 585–586
vascularization, 585
regeneration in the central nervous system, 592–595
inhibitory factors, 594–595
nerve growth factor in, 594
Schwann cells in, 592
substrate factors in, 592, 594
regional analyses of grafts, 595–608
cerebellum, 595–596
hippocampus, 596–598
in aged animals, 598
aminergic and cholinergic tissue grafts, 596–597
hippocampal tissue grafts, 597
hypothalamus, 598–601
in Brattleboro rat, 600–601
in hypogonadal mouse, 598–600
striatum, 601–603
substantia nigra, 603–608
adrenal medulla tissue, 606
cell lines and genetically modified cells, 606–607

clinical work, 607–608
fetal substantia nigra tissue, 603–606
Intraocular competition, retinogeniculate axon arbor development and (cat), 537–541
binocular effects of strabismus, 540
binocular competition without advantage, 540
cues associated with misaligned visual axes, 540
disruption of correlated activity along lines of projection, 540
dark rearing and, 541
factors controlling intralaminar size of X and Y arbors, 539–540
intralaminar postnatal development of X and Y retinogeniculate axons, 537–538
X and Y axon competition within LGN laminae, 538–539
effects of postnatal monocular enucleation within LGN laminae, 538
monocular eyelid suture and, 538
strabismus and, 538–539
tetrodotoxin treatment and, 538
Ion(s), blood-brain barrier transport, vasopressin and, 509

J

Joints, tachykinin functions in, 264–265

K

Kainate, neurotoxicity, 324–325
Kainate receptors, in cochlea, 322–324
Kidney
developing, taurine in, 134
endothelin actions, 389–398. *See also* Endothelin, renal actions
endothelin gene expression and secretion, 389–390
endothelin receptors
molecular characterization of renal endothelin binding sites, 389
receptor autoradiography in situ, 388
interstitial fluid hydrostatic pressure, capsule technique, 19
organic anion transport, 765–777
basolateral entry, 768–772
anion exchange, 768–769
indirect sodium coupling, 769–771
physiological counterion, 771–772
sodium dependence, 768
binding, 767
general features, 766–768
intracellular events, 772–773
luminal exit, 773–774
mechanism, 768–774
basolateral entry, 768–772
intracellular events, 772–773
luminal exit, 773–774
perspectives, 787–788
reabsorption, 767–768
site, 766
specificity, 766–767
urate and related renal systems, 774–775
reabsorption, 774–775
secretion, 775
organic cation transport, 777–787
basolateral entry, 780–781
facilitated diffusion, 780–781
renal tubular uptake, 781
general features, 777–779
intracellular sequestration, 781–782
luminal exit, 782–784
efflux through the multidrug transporter, 783–784
organic cation-proton antiport in, 782–783
perspectives, 787–788
reabsorption mechanisms, 785
secretion in vitro, 779
secretion in vivo, 777–778
secretory transport mechanisms, 780–784
basolateral entry, 780–781
intracellular sequestration, 781–782
luminal exit, 782–784
three-step mechanism for secretion, 784
site of secretion, 778
species differences, 778
specificity, 778–779
pathophysiology, possible role of endothelin, 396–398
sodium excretion, endothelin and, 393–395
tachykinin function in, 263
water reabsorption, endothelin and, 395–396

L

Lens of eye, developing, taurine in, 131–134
Leukocyte(s), activation, in inflammation, tachykinins and, 266–267
Limbic system, tachykinin functions in, 250
Liver
developing, taurine in, 134
organic anion transport, 775–776
bile acids in, 776
bile pigments in, 776
organic cation transport, 786–787
zinc uptake, 92
Locus coeruleus, tachykinin functions in, 253
Lung
interstitial edema-preventing mechanisms
hydrostatic buffering, 26
oncotic buffering, 27–28
interstitial fluid hydrostatic pressure
capsule technique, 18–19
micropuncture technique, 20
wick technique, 20
lymph, protein concentration, 16
Lymph
filling of initial lymphatics, 32–37
interstitial fluid pressure and volume and, 34–36
osmotic mechanism, 33–34
suction by collecting lymphatics, 36–37
vesicular transport, 33
flow
in congestive heart failure, 54–55
external work and power, 50–52
afterload and, 52
inotropic and chronotropic stimuli, 52
preload and, 52
functional hypertrophy of lymph vessels and, 52–53
in hyperfiltration states, 53–60
lymphatic buffering of interstitial fluid volume, 57–60
lymphatic safety factor in, 59–60
lymph flux-to-capillary filtration coefficient ratio during control conditions, 57–59
hypoproteinemia and, 56–57
intravenous infusion of salt solutions and, 55–56
in local venous stasis and orthostasis, 54
outflow resistance and, 47–50

effect of increased outflow pressure on lymph formation and capillary filtration, 49–50
peripheral lymphatics, 48–49
thoracic duct, 47
resistance to flow in lymphatic system, 44–45
formation, 32–37
filling of initial lymphatics, 32–37
increased outflow pressure and, 49–50
interstitial fluid transport and, 32
transport from initial lymphatics to valve-containing ducts, 37
vis a terago role in, 37
modification in lymph vessels and nodes, 45–47
fluid exchange in collecting lymphatics, 46–47
fluid exchange in lymph nodes, 46
protein exchange, 45–46
propulsion in collecting ducts, 37–44
active spontaneous contractions, 40–44
bradykinin and, 43
contractile mechanisms, 40–41
eicosanoids and, 43–44
endotoxin and, 44
histamine and, 43
humoral and neural influences, 41–42
origin and spread of contractions, 41
pharmacological and autocoid influences, 42–44
serotonin and, 43
blood vessel pulsation and, 39–40
external compression and massage and, 39
extrinsic propulsion mechanisms, 38–40
intestinal peristalsis and, 38
limb movements and, 38–39
respiration and, 38
protein concentration, 15–16
transport from initial lymphatics to valve-containing ducts, 37
Lymphatic system
distribution and anatomy of lymph vessels, 30–32
functional hypertrophy of lymph vessels and, 52–53
lymph formation, 32–37. *See also* Lymph
resistance to lymph flow in, 44–45
Lymphedema, 28–29

M

Massage, lymph propulsion in collecting ducts and, 39
Matrigel, in tumor invasion studies, 171
Matrix metalloproteinases. *See* Proteinases
Mechanical stimulation
pain induced by, 649
in psychophysiological pain studies, 640–641
Mesenteric ganglion, inferior, substance P in (guinea pig), 235–236
Metallothionein, zinc, 86–87
Metastatic disease. *See* Tumor invasion
***N*-Methyl-D-aspartate,** neurotoxicity, 325–326
***N*-Methyl-D-aspartate receptors,** in cochlea, 322
Microneurography, in psychophysiological pain studies, 646–648
Micropuncture technique, interstitial fluid hydrostatic pressure measurement, 20–21
Mitochondria, calcium regulation in blood cells and, 559
Molecular biology
endothelin genes, 380–382
senescence in vitro, 629–631
Morphine, tachykinins and, 244
Musculoskeletal system, tachykinin functions in, 264–265
Myocardial ischemia, α_1-adrenoceptor density changes during, 472
Myocardium
α_1-adrenoceptors in, 469–481
density and species dependence, 470–472
effector mechanisms, 479–481
inositol phosphates and elevation of intracellular calcium concentration, 481
phosphodiesterase and phospholipase activation, 479–480
protein kinase C and sodium-hydrogen exchange, 480–481
mechanical and electrical effects of α_1-adrenoceptor agonists, 473–478
contractility effects in vivo and in vitro, 473
effects on calcium currents, 474–475
effects on intracellular sodium, 475
effects on potassium currents, 473–474
overall effects on electrical activity, 475–476
summary of hypotheses for positive inotropic effect of α_1-adrenoceptor activation, 476–478
receptor density changes during ischemia and altered thyroid states, 472–473
structural aspects of transduction system, 478–479
α_1-adrenoceptors, 478–479
guanine nucleotide-binding protein coupling, 479
α_1- vs. α_2-adrenoceptors and subtypes, 469–470
changes with aging. *See also* Cardiovascular aging
in animals, 440–441, 442–452
levels of cardiac output during rest and light activity, 737
membrane and excitation-contraction events, 733–736
animal studies, 733–734
in human subjects, 734–736
pacemaker activity and heart rate, 736–737
contractile properties
effect of α_1-adrenoceptor agonists, 473
at rest, changes with aging, 423
excitation-contraction coupling mechanisms, 441–442
similar effects of aging and experimental pressure overload, 448–450
stiffness, changes with aging, in animals, 446–447
Myxedema, 29

N

Neocortex, tachykinin functions in, 246
Neoplasia
angiogenesis, proteinases in, 184–185
invasiveness and metastasis. *See also* Tumor invasion
zinc and, 104–105
Nerve growth factor
regeneration in CNS and, 594
tachykinins and, 244
Nervous system
central
control of gastroduodenal bicarbonate secretion, 831–833
grafting in. *See* Intracerebral grafting
tachykinin functions in, 246–254. *See also* Tachykinins
zinc deficiency and, 102
zinc in, 95–96
peripheral, zinc deficiency and, 102
sympathetic, modulation of cardiovascular function, 429–436. *See also* Cardiovascular aging
Neural tissue, interstitial fluid hydrostatic pressure, micropuncture technique, 20
Neurokinin A. *See* Tachykinins
Neurokinin B. *See* Tachykinins
Neuroreceptors, zinc and, 95–96

Neurotransmission, zinc in, 96
Neurotransmitters, 230–231
elaboration during stress, 429–430
hair cell, 316–328. *See also* Cochlea
of mammalian cochlea, 309–354. *See also* Cochlea
tachykinins, 229–270. *See also* Substance P; Tachykinins
Neutrophil activation, 797–801
chemotactic agonists, 798
classical signal transduction sequence, 798–799. *See also* Neutrophil signal transduction
exocytosis, 797–798
respiratory burst, 798
shape change, 797
Neutrophil signal transduction
calcium-independent, 799
chemoattractant receptors, 801–802
interaction with effector molecules, 802
structure, 801–802
classical sequence, 798–799
agonist-receptor interaction, 798
cytosolic free calcium in, 799
guanosine 5′-triphosphate-binding proteins in, 798
protein kinase C in, 799
second messenger generation, 798–799
control of different responses, 799
guanosine 5′-triphosphate-binding proteins in, 798, 802–804
heterotrimeric GTP-binding proteins, 803–804
small GTP-binding proteins, 804
phospholipases in, 804–806
phosphatidylcholine-specific phospholipase C, 805
phosphatidylinositol-specific phospholipase C, 804–805
phospholipase A_2, 805–806
phospholipase D, 806
protein kinases in, 806–807
serine/threonine phosphorylation, 806–807
tyrosine phosphorylation, 807
reduced nicotinamide adenine dinucleotide phosphate oxidase and its components, 807–810
cytochrome b_{558}, 808–809
cytosolic factors p47-*phox* and p67-*phox*, 809
guanosine 5′-triphosphate-binding proteins, 809–810
nucleotide-binding proteins, 809
phosphorylations, 809
Nicotinamide adenine dinucleotide phosphate (reduced) oxidase, 807–810
cytochrome b_{558}, 808–809
cytosolic factors p47-*phox* and p67-*phox*, 809
guanosine 5′-triphosphate-binding proteins and, 809–810
nucleotide-binding proteins, 809
phosphorylations, 809
Nociceptors, in pain perception, 645–652. *See also* Pain, psychophysiological studies
Norepinephrine, modulation of pacemaker currents, 214–215
Nucleus accumbens, tachykinin functions in, 249
Nucleus basalis of Meynert, tachykinin functions in, 249–250
Nucleus tractus solitarii, tachykinin functions in, 252

O

Oocyte, zinc in, 92
Opioids. *See also* Dynorphins; Enkephalins
tachykininergic transmission in spinal cord and, 235
Oral cavity, tachykinin functions in, 256–257
Organ of Corti
afferent innervations, 310–313
inner hair cell afferent innervation, 310–313
outer hair cell afferent innervation, 313
efferent olivocochlear innervations, 313–315
lateral efferent innervations, 313–314
origin, 313–314
projections, 314
medial efferent innervations, 314–315
origin, 314
projections, 314–315
neuronal circuitry, 310–316
Orthostasis, lymph flow response, 54
Oxygen consumption, myocardial, changes with aging, in animals, 448

P

Pain
chemically induced, 649
heat-induced, 648–649
mechanically induced, 649
psychophysiological studies, 639–660
assessment of pain perception, 644–645
pain threshold, 644
scaling of pain perceptions, 645
sensory decision theory methods, 644–645
differential blocking of axons, 642–643
differentiation between first and second pain, 643
event-related brain potentials and pain sensation, 652–659
event-related brain potentials (ERPs) and pain sensation. *See also* Event-related potentials
early near-field ERPs, 652–653
effects of analgesics on ERPs and pain ratings, 656–659
intermediate and late near-field ERPs, 653–655
pain-related potentials in neurology and related fields, 659
ultralate ERPs, 655–656
nociceptor discharges and pain sensation, sensitization of nociceptors and hyperalgesia, 651–652
nociceptor discharges and pain sensations, 645–652
chemically induced pain, 649
coincidence of nociceptor discharge and pain, 648–649
heat-induced pain, 648–649
mechanically induced pain, 649
microneurography and microstimulation of nerve fibers in humans, 646–648
nociceptor classes possibly contributing to pain perception, 645–646
nociceptor fatigue and pain, 651
quantitative aspects of nociceptor activation and pain, 649–651
stimulus and pain intensity, 649–650
time course of nociceptor activation and pain, 650–651
stimulation methods, 639–642
chemical irritants, 641–642
cold stimuli, 641
electrical stimuli, 639–640
heat stimulation, 641
mechanical stimuli, 640–641
natural stimulation, 640
threshold, 644
Pain transmission, in spinal cord
neurokinin A and, 235
substance P and, 234
Pancreas
acinar cell function, cholecystokinin and, 701–702. *See also* Cholecystokinin; Cholecystokinin receptors
tachykinin function in, 260–261

Parkinson's disease
intracerebral grafting in, 607–608
tachykinins in, 268
Pepsin, gastric, gastroduodenal mucosal protection. *See* Gastroduodenal mucosal protection
Peptides, 489. *See also* Neurotransmitters; *specific peptides*
blood-brain barrier receptors, 502–507
blood-brain barrier transport and, 490–514. *See also* Blood-brain barrier
renal, 375. *See also* Endothelin, renal actions
Peripheral vascular resistance
dynamic exercise and, changes with aging, 429
orthostatic stress and, changes with aging, 425
Phosphodiesterase, activation, myocardial α_1-adrenergic stimulation and, 479–480
Phospholipase(s)
activation, myocardial α_1-adrenergic stimulation and, 479–480
in neutrophil signal transduction, 804–806
Phospholipase A_2
calcium regulation in blood cells and, 562
in neutrophil signal transduction, 805–806
Phospholipase C
activation, cholecystokinin receptor signal transduction and, 709–710
calcium regulation in blood cells and, 560–561
phosphatidylcholine-specific, in neutrophil signal transduction, 805
phosphatidylinositol-specific, in neutrophil signal transduction, 804–805
Phospholipase D
calcium regulation in blood cells and, 562
in neutrophil signal transduction, 806
Pituitary gland, tachykinin functions in, 251
Plasma, tachykinins in, 269
Plasma proteins, interstitium, 5
Plasminogen activators. *See* Proteinases
Postsynaptic potentials, excitatory (EPSPs)
in prevertebral ganglia
neurokinin A and, 236
substance P and, 236
in spinal cord, substance P-mediated, 234–235
Potassium channels
adenosine-sensitive, 217
adenosine 5'-triphosphate-sensitive, 217–218
in blood cells, calcium regulation and, 557
Potassium currents
acetylcholine-activated, molecular pharmacology, 216
acetylcholine-sensitive, 215–216
delayed rectifier current, 205–206
absence, oscillation of membrane potential and, 213
effects of β-adrenergic agonists, 215
in pacemaker depolarization, 211
myocardial, effect of α_1-adrenoceptor agonists, 473–474
in sinoatrial node, 205–207
Pregnancy, trophoblast invasion, 177
Protein(s)
plasma. *See* Plasma proteins
transcapillary transport, 23–26
zinc, 86–90
Proteinases
extracellular matrix-degrading, 165–170
in tumor angiogenesis, 184–185
in tumor invasion, 170–184, 185–187. *See also* Tumor invasion, proteinases in
in trophoblast invasion, 177
in tumor invasion. *See* Tumor invasion
Protein kinase
in cardiovascular aging, 433–435
in neutrophil signal transduction, 806–807
Protein kinase A, calcium regulation in blood cells and, 562
Protein kinase C
calcium regulation in blood cells and, 561–562
in neutrophil signal transduction, 799, 806–807
in sodium-hydrogen exchange, myocardial α_1-adrenergic stimulation and, 480–481
Protein serine/threonine phosphatases, 673–692
catalytic mechanism, 680
in cell growth and division, 684–692
control of cell cycle, 684–690
growth factor signaling pathways, 690–692
classification, 674
Drosophila protein phosphatases, 679
expression of, 680–681
mammalian protein phosphatases, 679
protein phosphatase 1, 674
in control of cell cycle, 685–687
inhibitor proteins, 681–682
regulation of, 681–683
structure and isozyme diversity, 674–676
targeting subunits, 682–683
protein phosphatase 2A, 674
in control of cell cycle, 687–689
regulation of, 683
structure and isozyme diversity, 676–677
protein phosphatase 2B (calcineurin), 674
regulation of, 683–684
structure and isozyme diversity, 677–678
protein phosphatase 2C, 674
structure and isozyme diversity, 678
regulation of, 681–684
S. cerevisiae protein phosphatases (SIT4), 678–679
in control of cell cycle, 689–690
structures and isozyme diversity, 674–679
substrate specificity, 679–680
Protons, intracellular, modulation of pacemaker currents, 218
Psychophysiology of pain, 639–660. *See also* Pain, psychophysiological studies

Q

Quisqualate, neurotoxicity, 325

R

Raphe nuclei, tachykinin functions in, 253
Reflection coefficient, capillary, 22
transcapillary protein transport and, 24
Renin-angiotensin-aldosterone system, endothelin and, 394–395
Reproduction, taurine and, 119–121
Reproductive system, zinc physiology, 92–95
Respiration, lymph propulsion in collecting ducts and, 38
Respiratory burst. *See also* Nicotinamide adenine dinucleotide phosphate (reduced) oxidase
activation of. *See* Neutrophil signal transduction
Respiratory control, central, tachykinin functions in, 252–253
Respiratory system, tachykinin function in, 261–262
Retina
cell death in, 535–536
developing, taurine in, 131–134

tachykinin functions in, 255–256
zinc in, 97
Retinogeniculate system (cat), 529–542
competition and development of retinal axonal arbors
intralaminar size and, 541
location of projections, 541
retinogeniculate development, 531–532
roles of activity and light in development, 541–542
competition and development of retinal axonal arbors in lateral geniculate nucleus, 529–542. *See also* Interocular competition; Intraocular competition
development, 531–532
retinal ganglion cell development, 531
retinal projections in lateral geniculate nucleus, 531–532
lateral geniculate nucleus anatomy, 530
morphology
retinal ganglion cells, 530
retinogeniculate axon arbors, 530–531
retinogeniculate axon arbor development, 531–532. *See also* Interocular competition; Intraocular competition
Rheumatoid arthritis, zinc and, 103–104
Riley-Day syndrome. *See* Familial dysautonomia

S

***S. cerevisiae* protein phosphatases (SIT4),** 678–679
in control of cell cycle, 689–690
Sacral parasympathetic nucleus, tachykinin functions in, 254
Saline, intravenous infusion, lymph flow response, 55–56
Salivary glands, tachykinin functions in, 256–257
Scales/scaling, pain perceptions, 645
Schizophrenia, tachykinins in, 268
Schwann cells, regeneration in CNS and, 592
Senescence in vitro, 150–151, 617–632
cellular markers, 620–621
changes in cell size, morphology, and contact, 620–621
changes in macromolecular content and synthesis, 621
correlations with in vivo aging, 151, 618–620
dominance of senescent phenotype in cultured cells, 151
error catastrophe theory, 153–154, 627
free radical damage theory, 153, 627
genetic hypotheses, 155–157, 624–627
chromosomal location of putative senescence-specific genes, 626–627
evidence from heterokaryon studies, 624
immortality and senescence, 625
inhibitors of DNA synthesis, 624
mortality 1 and mortality 2 stages of senescence, 625–626
senescence and the quiescent state, 624–625
shortening of telomeres and telomere positional effects, 155, 626
historical background, 617–618
mechanisms, 624–627
genetic hypotheses, 624–627
stochastic or random error hypotheses, 627
modulation of DNA synthetic capacity and life span, 627–629
molecular markers, 629–631
differentially expressed genes: examination of genes isolated from selective libraries and monoclonal antibody pools, 630–631
differentially expressed genes: examination of pathways initiated by external signals or stimuli, 629–630
population dynamics, heterogeneity, and asynchronous changes, 621–624
cell cycle position of arrested cells, 622–623
chronological time and replications, 623–624
kinetics of DNA synthesis and cell division, 621–622
somatic mutation theory, 627
Sensory decision theory methods, in psychophysiological pain studies, 644–645
Serine phosphorylation, in neutrophils, 806–807
Serotonin, active lymph propulsion and, 43
Sexual behavior, substance P and, 251
Shortening telomere hypothesis, in cellular aging, 155, 626
Signal transduction
α_1-adrenoceptors in myocardium, 469–481
mechanisms of pancreatic cholecystokinin receptors, 709–710
neutrophils, 797–810. *See also* Neutrophil signal transduction
Sinoatrial node
calcium currents, 204–205
calcium ion selectivity, 204
conductance and kinetics, 204
types, 204–205
cardiac pacemaking in, 197–219
hyperpolarization-activated inward current, 207–209
cesium block of hyperpolarization-activated channel, 208
general characteristics, 207–208
hyperpolarization-activated channel in other tissues, 208
single-channel conductance, 208
unresolved issues, 208–209
inward background current, 209
membrane currents of cells, 201–210
calcium currents, 204–205
comparison with current-voltage relationships of atrial and ventricular cells, 203
current-voltage relationship of single sinoatrial node cell, 202–203
hyperpolarization-activated inward current, 207–209
inward background current, 209
potassium currents, 205–207
pump and exchange currents, 209
sodium-calcium exchange current, 209–210
sodium current, 203–204
sodium-potassium pump current, 209
pacemaker cells, 198–201
isolation and criteria, 198–199
single cell vs. multicellular preparations, 200–201
spontaneous electrical activity, 199
voltage-clamp experiments, 199–200
potassium currents, 205–207
absence of inwardly rectifying current, 206–207
acetylcholine-sensitive potassium channel background activity, 207
delayed rectifier current, 205–206
single-channel conductance, 205
voltage dependence of time constant of, 206
whole cell data, 205–206
transient outward current, 206
sodium-calcium exchange current, 209–210
sodium current, 203–204
sodium-potassium pump current, 209
Skeletal muscle
developing, taurine in, 134
interstitial edema-preventing mechanisms
hydrostatic buffering, 26
oncotic buffering, 26–27
interstitial fluid hydrostatic pressure, wick technique, 19–20
lymph, protein concentration, 15–16
tachykinin functions in, 264
Skin
interstitial edema-preventing mechanisms
hydrostatic buffering, 26
oncotic buffering, 26–27
interstitial fluid hydrostatic pressure

capsule technique, 18
wick technique, 19–20
lymph, protein concentration, 15–16
tachykinin functions in, 265
zinc deficiency and, 101
Sodium
intracelllar, myocardial, effect of α_1-adrenoceptor agonists, 475
renal excretion, endothelin in, 393–395
Sodium-calcium exchange, in blood cells, 556
Sodium-calcium exchange current, in sinoatrial node, 209–210
Sodium current, in sinoatrial node, 203–204
Sodium-potassium pump, in blood cells, calcium regulation and, 557
Sodium-potassium pump current, in sinoatrial node, 209
Somatic mutation theory, 627
Spectroscopy, zinc, 81–82
Spermatozoa, zinc in, 92
Spinal cord
nociception
neurokinin A in, 235
substance P in, 234
substance P as sensory transmitter in, 232–235
Spinal trigeminal nucleus, tachykinin functions in, 251–252
Steroid hormone receptors, binding domains, zinc and, 96–97
Stomach
acid disposal, 836–841
mucosal blood flow in hydrogen ion disposal, 838–840
permeability of gastric epithelium to hydrogen ions, 836–838
protective role of interstitial bicarbonate, 840–841
regulation and maintenance of intracellular pH, 841
bicarbonate secretion, 827–828
mucosal protection. *See* Gastroduodenal mucosal protection
Strabismus
binocular effects on retinogeniculate axon development (cat), 540
competition between X and Y retinogeniculate axons during development and (cat), 548–539
Stress
cardiovascular response to, changes with aging, 425–429
neurotransmitter elaboration during, 429–430
orthostatic, cardiovascular response to, changes with aging, 425–426
pressor, cardiovascular response to, changes with aging, 426–427
Striatum
intracerebral grafting in, 601–603
tachykinin functions in, 246–248
Substance P. *See also* Tachykinins
blood-brain barrier transport and, 513
enzymatic degradation, 243–244
history of, 231–232
intracellular calcium and, 243
membrane effects, 242–243
neurotransmitter role in primary afferent neurons, 232–236
development of neurotransmitter concept, 232
as sensory transmitter in spinal cord, 232–235
in prevertebral ganglia, 235–236
action of substance P and slow excitatory postsynaptic potentials, 235
evidence for, 235
functional significance, 235
release of, 235
as sensory transmitter in spinal cord, 232–235
distribution of substance P, 233
effects of substance P and stimulation of primary afferents, 233–234
interaction of opioids with tachykininergic transmission, 235
pain transmission, 234
release of substance P, 233
substance P-mediated excitatory postsynaptic potentials, 234–235
Substantia nigra
intracerebral grafting in, 603–608
adrenal medulla tissue, 606
cell lines and genetically modified cells, 606–607
clinical work, 607–608
fetal substantia nigra tissue, 603–606
tachykinin functions in, 248–249

T

Tachykinins. *See also* Substance P
agonists, 239
in allergy, 268–269
in Alzheimer's disease, 268
antagonists, 239–241
development of new tachykinin antagonists, 240–241
effect on neurally evoked responses, 240
limitations in use of, 240
specificities, 239–240
antibodies to, 241
in arthritis, 269
axonal transport, 241
biosynthesis, 241
capsaicin studies, 241–242
effects on C-afferent neurons, 242
mechanism of action of capsaicin, 242
in carcinoid syndrome, 269
cardiovascular and arousal reaction and, 251
cellular and molecular aspects, 236–246
biosynthesis, storage, and axonal trasnport, 241
capsaicin studies, 241–242
cellular mechanisms of tachykinin action, 242–243
coexistence of tachykinins with other neurotransmitters, 245–246
distribution of tachykinins and their messenger RNA, 237–238
inactivation mechanisms of tachykinins, 243–244
long-term changes in tachykinin system, 244–245
precursor peptides and genes, 237
release, 241
structure-activity relationship and tachykinin agonists, 239
tachykinin antagonists, 239–241
tachykinin receptors, 238–239
cellular mechanisms of tachykinin action, 242–243
G proteins in tachykinin actions, 243
membrane effects of tachykinins, 242–243
second messenger systems, 243
tachykinin-induced elevation of intracellular calcium, 243
central respiratory control and, 252–253
in chronic bowel inflammation and constipation, 269
coexistence with other neurotransmitters, 245–246
5-hydroxytryptamine and thyrotropin-releasing hormone in ventral medullary neurons, 245
neurokinin A and calcitonin gene-related peptide in primary afferent neurons, 245
significance of, 246
conclusions
diversity of tachykinin system, 270
functions of tachykinins, 270
neurotransmitter families, 270
transmitter action, 269–270
discovery of, 236–237
disease and, 268–269
enzymatic degradation, 243–244
in familial dysautonomia (Riley-Day syndrome), 268

functions in central nervous system, 246–254
in amygdala and bed nucleus of stria terminals, 250
in ascending reticular system, 253
in autonomic preganglionic nuclei, 253–254
in dorsal vagal complex, 252–253
in glia, 254
in globus pallidus, 248
in habenulo-interpeduncular system, 250
in hippocampus, 250
in hypothalamus and pituitary gland, 250–251
in limbic system, 250
in locus coeruleus, 253
in neocortex, 246
in nucleus accumbens, 249
in nucleus basalis of Meynert, 249–250
in raphe nuclei, 253
in spinal trigeminal nucleus, 251–252
in striatum, 246–248
in substantia nigra, 248–249
in thalamus, 251
in ventral horn and cranial motor nuclei, 254
in ventral tegmental area, 249
functions in peripheral tissues, 254–265
adrenal glands, 264
blood vessels, 262
carotid body, 262–263
circulatory system, 262
dental pulp, 256
eye, 255–256
anterior segment, 255
retina, 255–256
gastrointestinal tract, 257–260
actions on enteric neurons and role as neurotransmitters, 258
gastrointestinal motility and, 258–259
secretion and, 259
vascular responses and mucosal protection, 259–260
heart, 262
hepatobiliary system, 260
musculoskeletal system, 264–265
bone and joints, 264–265
skeletal muscles, 264
oral cavity, 256–257
pancreas, 260–261
respiratory system, 261–262
salivary glands, 256–257
skin, 265
tongue, 256
urogenital system, 263–264
female genital organs, 264
kidney and ureter, 263
male genital organs, 264
urinary bladder, 263
future studies, 270
in headache, 269
in herpes zoster, 269
in Hirschsprung's disease, 268
in Huntington's disease, 268
in immune system, 267
inactivation mechanisms, 243–244
in inflammation, 265–267
flare and vasodilatation, 265–266
interaction with other mediators, 267
involvement of capsaicin-sensitive afferent fibers, 265
leukocyte activation, 266–267
wheal and plasma extravasation, 266
integrated functions of C-afferent neurons and, 267–268
long-term changes in tachykinin system, 244–245
C-afferent-induced long-lasting changes, 245
denervation supersensitivity, 245
experimental diabetes and, 244
morphine and, 244
nerve growth factor and, 244
noxious stimulation and, 244–245
membrane effects, 242–243
neurotransmitter functions, 229–270
in Parkinson's disease, 268
in plasma and cerebrospinal fluid, 269
precursor peptides and genes, 237
receptors, 238–239
distribution, 238–239
in gastrointestinal tract, 257
structures, 238
subtypes, 238
release, 241
in gastrointestinal tract, 257
in schizophrenia, 268
sensory transmission in spinal cord, 232–235
sexual behavior and, 251
storage, 241
structure-activity relationship, 239
in wound healing and trophic functions of C-afferent neurons, 267
Tapetum lucidum
developing, taurine in, 131–134
zinc in, 97–98
Taurine
in development, 119–136
brain, 126–131
heart, 134
kidney, 134
liver, 134
muscles, 134
reproduction and postnatal development, 119–126
retina, lens, and tapetum, 131–134
neuroactive effects in cochlea, 344
in tissue culture, 134–135
Testis, zinc in, 92
Tetrodotoxin, competition between X and Y retinogeniculate axons during development and (cat), 548
Thalamus, tachykinin functions in, 251
Threonine phosphorylation, in neutrophils, 806–807
Thyroid disorders, myocardial α_1-adrenoceptor density changes during, 472
Tissue culture, taurine in, 134–135
Tissue osmometry
interstitial colloid osmotic pressure, 17–18
interstitial fluid hydrostatic pressure, 17–18, 20
Tongue, tachykinin functions in, 256
Transmembrane signaling
α_1-adrenoceptors in myocardium. *See* Myocardium, α_1-adrenoceptors in
calcium regulation in blood cells, 560–564
arachidonic acid and phospholipase A_2 in, 562
1,2-diacylglycerol and protein kinase C in, 561–562
inositol 1,4,5-trisphosphate and phospholipase C in, 560–561
other intracellular messengers and related enzymes in, 562–563
endothelin, 382–387
Tumor(s), angiogenesis, proteinases in, 184–185
Tumor invasion
extracellular matrix alterations during, 164–165
proteinases in, 161–187
conclusion and perspectives, 185–187
diagnostic and prognostic implications, 183–184

extracellular matrix-degrading proteinases, 165–170
historical background, 170
in vivo reports, 180–183
proteolytic requirements, 173–184. *See also* Tumor invasion, proteolytic requirements for
study methodology, 170–173
degradation and/or invasion of an in vitro reconstituted extracellular matrix, 171
degradation of labeled extracellular matrix components, used singly or in combination, 170
degradation of metabolically labeled extracellular matrix or basement membrane formed by cultured cells, 171
invasion of chick chorioallantoic membrane and metastasis formation in embryo's lungs, 171–172
in vitro invasion through natural basement membrane, 171
repopulation and invasion of deepithelialized xenotransplanted rat trachea, 171
tumor cell colonization and/or metastasis formation in laboratory animals, 172–173
proteolytic requirements for, 173–184
concerted proteolytic activities in, 178–179
degradative enzymes other than plasminogen activators and matrix metalloproteinases, 177–178
modulation of proteolytic activity in metastatic cells, 183
proteinases in extracellular matrix degradation and tumor invasion in vitro, 174–177
proteinases in trophoblast invasion: similarities with tumor invasion, 177
quantitative proteolytic requirements, 179–180
tumor cell degradation of selected extracellular matrix components, 173–174
zinc and, 104–105
Tyrosine phosphorylation, in neutrophils, 807

U

Urate, renal transport, 774–775
Ureter, tachykinin function in, 263
Urinary bladder, tachykinin function in, 263
Urogenital system, tachykinin functions in, 263–264

V

Vagal ganglia, tachykinin functions in, 253
Vascularization, in intracerebral grafting, 585
Vascular system, age-related effects, 737–746. *See also* Cardiovascular aging, vascular system
Vasoactive intestinal peptide, blood-brain barrier transport and, 513
Vasopressin
blood-brain barrier receptors, binding characteristics and signaling pathways, 503–504
blood-brain barrier transport and, 508–510
amino acid transport, 508–509
hemodynamic effects, 509–510
tight junction permeability and, 509
water and ion transport, 509
Venous stasis, local, lymph flow response, 54
Ventral horn, tachykinin functions in, 254
Ventral tegmental area, tachykinin functions in, 249
Vesicles, calcium regulation in blood cells and, 559–560
Visual system, developing, taurine in, 131–134

W

Water, blood-brain barrier transport, vasopressin and, 509
Wick techniques
interstitial fluid hydrostatic pressure measurement, 19–20
interstitial protein concentration, 16–17
Wound healing, tachykinins in, 267

X

X axon. *See* Retinogeniculate system

Y

Y axon. *See* Retinogeniculate system

Z

Zinc
absorption and excretion, 91
biochemistry, 81–86
chemistry, 81
deficiency, 100–101
dermatologic disorders and, 101
endocrine disorders and, 102
gastrointestinal disorders and, 101–102
hematologic disorders and, 102–103
neurologic disorders and, 102
organ pathology, 101–103
in developmental biology, 93–95
chromatin, 93
gene regulatory proteins, 94–95
replication and transcription enzymes, 93–94
in endocrine system, 96–97
enzymes, 82–86
catalytic zinc atoms, 83–85
coactive (cocatalytic) zinc atoms, 85
structural zinc atoms, 85–86
zymogen activation, 86
excess, adverse effects, 99–100
in gastrointestinal system, 91–92
in immune system, 98–99
interface of biochemistry and physiology, 90–91
in invasiveness and metastasis of neoplasia, 104–105
liver uptake, 92
in neural system, 95–96
neuroreceptors, 95–96
neurotransmission, 96
in ocular system, 97–98
overview, 80–81
physiology, 79–105
plasma transport, 91–92
proteins, 86–90
gene regulatory proteins, 87–90
metallothionein, 86–87
in reproductive system, 92–95
developmental biology, 93–95
embryonic development and, 92–93
sperm and oocytes, 92
rheumatoid arthritis and, 103–104
spectroscopy, 81–82
toxicity, 99–100